Lymphocyte activation gene-3 (LAG-3, CD223) in plasmacytoid dendritic cells (pDCs): a molecular target for the restoration of active antitumor immunity.

PubWeight™: 0.81‹?›

🔗 View Article (PMID 25941596)

Published in Oncoimmunology on December 21, 2014


Chiara Castelli1, Frédéric Triebel2, Licia Rivoltini1, Chiara Camisaschi1

Author Affiliations

1: Unit of Immunotherapy of Human Tumors; Dept. of Experimental Oncology and Molecular Medicine; Fondazione IRCCS Istituto Nazionale dei Tumori ; Milano, Italy.
2: Immutep S.A.; Faculté de Pharmacie; Chatenay-Malabry ; France.

Associated clinical trials:

Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | NCT01968109

IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma | NCT00349934

Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies | NCT02061761

A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Subjects and Patients With Plaque Psoriasis | NCT02195349

Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides | NCT00365937

Phase I Study of IMP321 Given Alone or as an Adjuvant to a Reference Flu Antigen | NCT00354263